Stéphane Thiroloix
Founder at Algotherapeutix SAS
Profile
Stéphane Thiroloix is the founder and currently holds the position of President, Chief Executive Officer & Director at AlgoTherapeutix SAS, a company founded in 2018.
He is also currently working as Vice President-Business Development at Ipsen Pharma SA. In his former roles, Mr. Thiroloix served as a Director at DBV Technologies SA, Director-Business Development & Marketing at GlaxoSmithKline AG, Managing Director at Ipsen Pharma SAS, Vice President-Europe & General Manager-France at Bristol Myers Squibb Co., President-Europe ASD Division at Smith & Nephew plc, General Manager at Sanofi, Executive Vice President-Corporate Development at Ipsen SA, Vice President-Business Development at Ipsen International GmbH, and Member-Supervisory Board at Laboratoires Mayoly Spindler SAS.
Mr. Thiroloix completed his undergraduate degree at École des Hautes Études Commerciales de Paris in 1986.
Stéphane Thiroloix active positions
| Companies | Position | Start |
|---|---|---|
Ipsen Pharma SA
 Ipsen Pharma SA Pharmaceuticals: MajorHealth Technology Ipsen Pharma SA manufactures and distributes pharmaceutical products. It supplies products to the therapeutic areas such as oncology, endocrinology, and neuromuscular disorders. The firm also develops drugs for gastroenterology, cognitive disorders, and cardiovascular diseases. Ipsen Pharma is headquartered in Sant Feliu de Llobregat, Spain. | Corporate Officer/Principal | - |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Founder | 2017-12-31 |
Former positions of Stéphane Thiroloix
| Companies | Position | End |
|---|---|---|
| SMITH & NEPHEW PLC | Corporate Officer/Principal | - |
Laboratoires Mayoly Spindler SAS
 Laboratoires Mayoly Spindler SAS Pharmaceuticals: MajorHealth Technology Laboratoires Mayoly Spindler SAS engages in the development of pharmaceutical and dermatology services. The company was founded by Gaston Mayoly in 1929 and is headquartered in Chatou, France. | Director/Board Member | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | President | - |
GlaxoSmithKline AG
 GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Sales & Marketing | - |
Training of Stéphane Thiroloix
| École des Hautes Études Commerciales de Paris | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| IPSEN | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| SANOFI | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| SMITH & NEPHEW PLC | Health Technology |
| Private companies | 6 |
|---|---|
Ipsen Pharma SA
Ipsen Pharma SA Pharmaceuticals: MajorHealth Technology Ipsen Pharma SA manufactures and distributes pharmaceutical products. It supplies products to the therapeutic areas such as oncology, endocrinology, and neuromuscular disorders. The firm also develops drugs for gastroenterology, cognitive disorders, and cardiovascular diseases. Ipsen Pharma is headquartered in Sant Feliu de Llobregat, Spain. | Health Technology |
Ipsen International GmbH
 Ipsen International GmbH Industrial MachineryProducer Manufacturing Ipsen International GmbH manufactures and distributes furnaces and plant systems. Its products include sealed quench furnaces; chamber and multi-purpose chamber furnaces; horizontal and vertical furnaces; EcoFire system; HydroNit Sensor; HybridCarb; and EndoSave system. The firm also provides software processes such as Carb-o-Prof 4.0, AutoMag, Vacu-Prof, and Conti-Control. The company was founded by Harold Ipsen in 1957 and is headquartered in Kleve, Germany. | Producer Manufacturing |
GlaxoSmithKline AG
GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Health Technology |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
Laboratoires Mayoly Spindler SAS
Laboratoires Mayoly Spindler SAS Pharmaceuticals: MajorHealth Technology Laboratoires Mayoly Spindler SAS engages in the development of pharmaceutical and dermatology services. The company was founded by Gaston Mayoly in 1929 and is headquartered in Chatou, France. | Health Technology |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Health Technology |
- Stock Market
- Insiders
- Stéphane Thiroloix
